GlassScriptPhysician profile
Mark D Anderson
NPI 1922202415
$6,793.73
in general payments reported to CMS, 2019-2025
81 companies · $1,738 in 2025
The $1,738 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $711 · 2020: $410 · 2021: $1,207 · 2022: $1,246 · 2023: $575 · 2024: $906 · 2025: $1,738.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,882 · Travel and Lodging: $337.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,882.26 |
| Travel and Lodging | $336.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $570.75 | 2025 | |
| Abbvie INC. | $471.20 | 2021-2025 | Qulipta |
| Janssen Biotech, INC. | $355.98 | 2019-2025 | Tecvayli, Darzalex, Talvey |
| Amgen INC. | $355.80 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $341.55 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $278.25 | 2019-2025 | Iclusig, Alunbrig |
| Acadia Pharmaceuticals INC | $228.29 | 2020-2022 | |
| Pfizer INC. | $225.72 | 2021-2025 | |
| Exelixis INC. | $201.36 | 2019-2025 | Cabometyx |
| Incyte Corporation | $191.06 | 2019-2025 | Jakafi, Monjuvi |
| Horizon Therapeutics Plc | $184.36 | 2021-2023 | Uplizna |
| Genzyme Corporation | $163.67 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $155.71 | 2019-2025 | Keytruda, Welireg, Reblozyl |
| Sunovion Pharmaceuticals INC. | $144.88 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $107.91 | 2022 |
Show all 80 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Anderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.